What is the Biggest Problem with the US Healthcare System? It's Not What You Think

The United States spends an estimated $14,885 per person on healthcare—nearly double the average of comparable wealthy nations—and dedicates more than $1,000 per capita to administrative costs, approximately five times more than the average of other wealthy countries .

If money alone could buy health, the U.S. would be the healthiest nation on Earth. So what is the biggest problem with the US healthcare system? Most people point to insurance companies, drug prices, or malpractice lawsuits. While those are symptoms, the root cause runs deeper: a fundamental misalignment of incentives that rewards the wrong behaviors at every level of care.

What Is the Biggest Problem with the US Healthcare System? The Incentive Gap

When you ask policymakers, clinicians, and patients what's wrong with the US healthcare system, you will hear dozens of answers. Costs are too high. Outcomes are too low. Bills are impossible to decode. But beneath these complaints lies a single structural flaw: the people who profit from the system are rarely the same people who benefit from better health. As Fortune recently noted, providers and insurers often profit when patients require more treatment, not when they remain healthy, and this misalignment contributes to inefficiency leading to hundreds of billions in wasteful spending .

The consequences are measurable. The U.S. devotes 17.2 percent of its GDP to healthcare while achieving worse results on basic metrics like life expectancy and infant mortality . In the United States, life expectancy was 78.4 years in recent OECD data, 2.7 years below the OECD average, while preventable mortality stood at 217 per 100,000 people compared with the OECD average of 145 . We are paying more and receiving less, a paradox that only makes sense when you examine how the system incentivizes spending rather than healing.

The Fee-for-Service Trap: Why Quantity Trumps Quality

At the heart of the misalignment is the fee-for-service reimbursement model, which still dominates American medicine. Under FFS, providers bill separately for every test, scan, and consultation, creating a direct financial incentive to deliver more services regardless of whether those services improve patient outcomes. Studies suggest that up to 30 percent of healthcare spending in fee-for-service environments may be attributable to unnecessary or low-value services. The model also punishes coordination: because each specialist bills independently, there is little financial motivation to share records, align treatment plans, or avoid duplicate procedures.

Value-based care offers an alternative. By tying reimbursement to outcomes, quality metrics, and cost efficiency, VBC shifts the financial reward from volume to value. Medicare's Hospital Readmissions Reduction Program, for example, contributed to an 18 percent reduction in 30-day readmission rates by penalizing excessive returns. Yet the transition has been slow. Most healthcare systems still operate on hybrid models, and CMS aims to have 100 percent of Medicare fee-for-service beneficiaries aligned with an accountable care relationship only by 2030. Until then, the default incentive remains clear: do more, earn more.

The $1 Trillion Paperwork Problem: Administrative Waste

If you have ever wondered why a simple doctor's visit generates a bill the thickness of a novel, the answer lies in administrative bloat. U.S. healthcare administrative spending totals approximately $1 trillion annually, with the financial transactions ecosystem alone—claims processing, payment, collections, and prior authorization—accounting for roughly $200 billion in annual spending .

The numbers are staggering. The United States spends approximately $925 per capita on health administration, roughly triple the average across OECD nations, while private insurance companies spent $158 billion on administrative overhead in a single year and prior authorization alone costs the system $35 billion annually . Hospitals now spend more than 40 percent of total expenses on administrative functions related to delivering care, including nearly $18 billion annually just to overturn denied insurance claims. Compared with other wealthy nations, the disparity is embarrassing. While Canada's single-payer system allocates about 2 percent of total health expenditure to administration, the U.S. spends 8 percent.

When researchers analyzed waste categories across American healthcare, they found that billing errors and outright fraud represent the single largest category, and adjusted for current expenditure data, total annual waste now projects to approximately $1.6 trillion in 2025 . If that waste were a standalone economy, it would rank among the fifteen largest in the world.

Pharmacy's Patent Playground: How Drug Pricing Escalates

No discussion of healthcare costs is complete without addressing pharmaceuticals. Prescription drug prices in the United States are not merely high; they are systematically inflated by legal frameworks that suppress competition. One major tactic is patent thicketing, where drug makers obtain dozens or even hundreds of patents on a single branded product after FDA approval to block less expensive generics and biosimilars from entering the market.

The financial pressure on patients is relentless. Patent thickets on just five brand-name drugs cost U.S. consumers more than $16 billion in lost savings in a single year, while the median annual launch price of drugs approved by the FDA in 2023 reached $300,000, up 35 percent compared to the previous year . Meanwhile, Big Pharma spent nearly $8.1 billion on direct-to-consumer advertising in 2022, pushing brand-name medications that often offer marginal therapeutic value over older, cheaper alternatives. According to one analysis, fewer than one-third of the most commonly featured drugs in television advertising were rated as having high therapeutic value.

Employers feel the squeeze as well. Research from Aon and the Business Group on Health anticipates company healthcare costs will rise by 8 to 9 percent in 2025, driven in large part by blockbuster GLP-1 drugs and multimillion-dollar gene therapies. When pharmaceutical profit motives are protected by patent law rather than disciplined by market competition, patients and payers inevitably foot the bill.

Why Are Medical Bills So Hard to Understand? The Price Transparency Crisis

Perhaps no experience captures the dysfunction of American healthcare better than opening a medical bill. Charges appear without context, insurance adjustments read like cryptography, and the final amount owed often seems arbitrary. This opacity is not accidental. For decades, prices have been hidden from patients and employers, allowing hospitals and insurers to operate with insufficient accountability regarding their pricing practices.

The lack of price transparency makes patients powerless consumers. When you buy a car or a smartphone, you compare features and prices before purchasing. In healthcare, you often do not know the cost until after the service is rendered, and sometimes not even then. One economic analysis estimated that fully implemented price transparency regulations could result in as much as $80 billion in healthcare savings by 2025, and early data found that the top 25 percent of most expensive healthcare service prices dropped by 6.3 percent per year following initial implementation .

Recent federal efforts have attempted to correct this. Regulations now require hospitals to maintain consumer-friendly displays of pricing information for up to 300 shoppable services and machine-readable files with negotiated rates for every service provided. Health plans must post their negotiated rates and maintain internet tools through which individuals can access price information. Yet enforcement has been inconsistent, and many facilities still treat pricing data as a trade secret rather than a patient right.

What's Wrong with the US Healthcare System? Connecting the Dots

When you step back, the pattern becomes clear. The fee-for-service model incentivizes more procedures, which generates more bills, which require more administrators to process, which raises premiums, which forces insurers to restrict access through prior authorization, which frustrates doctors and delays care for patients. Meanwhile, drug manufacturers exploit patent laws to extend monopolies, and hospitals hide prices to avoid competitive pressure. Every actor is responding rationally to the incentives in front of them. The problem is that those incentives are structurally misaligned with the goal of keeping people healthy.

The result is a system that excels at generating revenue but struggles to produce wellness. The United States has fewer practicing doctors per capita and fewer hospital beds than the OECD average, yet it has far more advanced imaging machines per million population. We have more machines than beds, more administrators than nurses, and more costs than outcomes. That is not a healthcare system optimized for patients. It is a financial system optimized for transactions.

How to Improve the US Healthcare System: Aligning Incentives for Value

Fixing American healthcare does not require a single magic bullet. It requires rewiring the incentives that shape behavior across the entire ecosystem. First, accelerating the shift from fee-for-service to value-based care would align provider compensation with patient outcomes rather than service volume. Second, standardizing and automating administrative processes could save $40 billion to $60 billion annually by adopting centralized claims clearinghouses and reducing prior authorization burdens. Third, reforming patent law to prevent thicketing and speed generic entry would introduce real competition into pharmaceutical markets.

On the transparency front, enforcing existing price disclosure rules—and empowering employers to shop for care using actual negotiated rates—could introduce market forces that drive value. When employers can compare carriers' prices using actual dollar amounts rather than percentage discounts off inflated chargemasters, they can steer employees toward high-quality, reasonably priced providers and find significant savings . Finally, regional healthcare innovation "sandboxes" could allow local experimentation with new payment and delivery models, generating insights that scale nationally.

The good news is that the tools exist. The challenge is political will. Every wasted dollar, every denied claim, and every inflated drug price represents a constituency with a lobbyist in Washington. Changing the system means confronting those interests with data, transparency, and a clear moral argument: healthcare should be measured by the health it creates, not the wealth it extracts.

Key Takeaways

• The U.S. spends nearly $14,885 per capita on healthcare—almost twice the average of comparable wealthy nations—but achieves worse outcomes on life expectancy and preventable mortality.
• The core problem is not any single industry actor but a systemic misalignment of incentives that rewards volume over value, sickness over prevention, and opacity over transparency.
• Fee-for-service reimbursement encourages providers to deliver more procedures regardless of whether they improve patient health, driving up costs without improving outcomes.
• Administrative waste consumes roughly $1 trillion annually, with billing complexity, prior authorization, and claims disputes diverting resources away from actual patient care.
• Pharmaceutical patent thicketing and direct-to-consumer advertising inflate drug prices, with just five drugs costing consumers over $16 billion in lost generic savings in one year.
• The lack of price transparency leaves patients powerless to comparison-shop, while fully enforced transparency rules could save up to $80 billion by 2025.
• Value-based care models that tie reimbursement to outcomes and quality metrics offer a proven alternative to fee-for-service, but adoption remains slow.
• The U.S. spends roughly triple the OECD average on health administration per capita, with hospitals dedicating over 40 percent of expenses to bureaucratic functions.
• Employers and patients alike can drive change by demanding clear pricing data, reference-based purchasing, and accountability from insurers and providers.
• Sustainable improvement requires coordinated reforms across payment models, administrative simplification, patent law, and price transparency—not isolated fixes.